PET scan study for prostate cancer with low PSMA or neuroendocrine features
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer that either has low PSMA levels on a standard PSMA PET scan or has been confirmed as neuroendocrine by biopsy
- You have at least 5 metastatic tumors
- You are 18 years or older
- You are willing to use contraception during the study and for 24 hours after the PET scan
- You have not had a severe allergic reaction to similar compounds
- You do not have other cancers requiring treatment or uncontrolled health issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.